Clinical trial NCT01322048: DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
Official title: DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Severe Traumatic Brain Injury, A Pilot Randomized Clinical Trial Using Propranolol and Clonidine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Brain Injuries
Craniocerebral Trauma
Trauma, Nervous System
Traumatic Brain Injury
Keywords: Sympathetic Hyperactivity
Traumatic Brain Injury
Agitation
Severe TBI
TBI
Catecholamines
Heart rate variability
Adrenergic alpha-Agonists
Adrenergic beta-Antagonists
Cognitive Impairment
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: Vanderbilt University Medical Center
name: Eastern Association for the Surgery of Trauma (EAST)
First posted: 2011-03-24
Enrollment: 48
Sex: ALL
Minimum age (years): 16
Maximum age (years): 64
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI).

The primary hypothesis is that adrenergic blockade after severe TBI will be associated with increased ventilator-free days.

Detailed description: Severe traumatic brain injury (TBI) is associated with sympathetic hyperactivity resulting in catecholamine excess, abnormal heart rate variability, agitation and sympathetic storms, deep white matter changes, and poor neuropsychological outcomes. Notably, persistent sympathetic hyperactivity after TBI results in higher days of mechanical ventilation and longer intensive care unit (ICU) length of stay (LOS). While there are data describing limited portions of this response, the full spectrum of sympathetic hyperactivity after severe TBI has not been systemically described or methodically intervened upon.

We will perform a double-blinded, randomized, placebo-controlled pilot trial in a 100 patient cohort in which one group will receive centrally acting sympatholytic drugs, propranolol and clonidine, and the other group, placebo, within 48 hours of severe TBI. The length of therapy will be 7 days.

The primary question studied is whether ventilator-free days will be increased after therapy.

Secondary endpoints include plasma and urine catecholamine levels, heart rate and blood pressure variability, responses to autonomic cold pressor testing, assessments of coma, sedation, and agitation, sedative requirements, analgesic use, antipsychotic medication use, coma-free days, ventilator-free days, Intensive Care Unit (ICU) length of stay, and survival. Also, neuropsychological outcomes will be measured at ICU discharge, 3 months, and 12 months.

Interim Analysis: At approximately 50% targeted accrual, n=46 randomized subjects, an interim analysis will be performed with A Priori (planned) futility and efficacy rules, which are DSMB and IRB approved.

Eligibility criteria: Inclusion Criteria:

* Age: 16 years to 64 years
* Glasgow Coma Scale score less than or equal to 8 (Severe TBI) with injury on CT
* Screen within 24 hours of injury

Exclusion Criteria:

* Pre-existing heart disease (i.e. coronary heart disease)
* Pre-existing cardiac dysrhythmia
* Allergy to study drugs
* Penetrating brain injury
* Pre-existing brain dysfunction (i.e. prior severe TBI, debilitating stroke)
* Impending brain herniation (i.e. loss of bilateral corneal reflexes)
* Craniectomy or craniotomy
* Spinal cord injury
* Myocardial injury
* Severe liver disease
* Current use of beta-blockers and/or alpha-2-agonist
* Withdrawal of care expected in 24 hours
* Prisoners
* Pregnant women
* Unable to follow-up through final visit

Primary outcomes:
measure: Ventilator-free Days
timeFrame: Baseline to day 28
Secondary outcomes:
measure: Plasma Norepinephrine Levels
timeFrame: Post-treatment (t=Day 8)
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Mayur B Patel, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Patel MB, McKenna JW, Alvarez JM, Sugiura A, Jenkins JM, Guillamondegui OD, Pandharipande PP. Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial. Trials. 2012 Sep 26;13:177. doi: 10.1186/1745-6215-13-177.